* TELA Bio Inc TELA.OQ TELA.O is expected to show a rise
in
quarterly revenue when it reports results on March 21 for the
period ending December 31 2023
* The Malvern Pennsylvania-based company is expected to
report a
41.0% increase in revenue to $16.392 million from $11.62 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.The company's guidance on November 9 2023,
for the period ended December 31, was for revenue between $15.50
million and $18.50 million.
* LSEG's mean analyst estimate for TELA Bio Inc is for a
loss
of 43 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for TELA Bio
Inc is
$14.50, above its last closing price of $5.35.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.49 -0.49 -0.45 Beat 8.5
Jun. 30 2023 -0.53 -0.53 -0.46 Beat 13.7
Mar. 31 2023 -0.56 -0.56 -0.63 Missed -12.7
Dec. 31 2022 -0.51 -0.55 -0.52 Beat 4.8
Sep. -0.63 -0.63 -0.64 Missed -2.3
30 2022
Jun. 30 2022 -0.65 -0.62 -0.79 Missed -27.8
Mar. 31 2022 -0.56 -0.56 -0.75 Missed -34.5
Dec. 31 2021 -0.55 -0.59 Missed -7.8
This summary was machine generated March 19 at 21:30 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)